| Ra Pharmaceuticals–UCB: investment, 201910– acquisition $2.5b in cash for $48/share incl acquired net cash of $315m ANNOUNCED |
2019-10-10 |
| N-Side–Sciad Communications: public relations, 201910 service existent by Sciad |
2019-10-09 |
| Illumina–Qiagen: sequencing-based IVD tests, 201910–2034 collab 15y strategic alliance combining sequencing technology + assays + automation + s/w |
2019-10-07 |
| Immunexpress–SEVERAL: investment, 201910 private financing round |
2019-10-03 |
| Univercells–EU (govt): credit, 201910– EIB loan €20m to advance vaccine portfolio |
2019-10-03 |
| AstraZeneca–N-Side: clinical supply chain management s/w, 201910– supply implementation of cloud-based N-Side Suite for Clincial Trials |
2019-10-01 |
| Cellectis–Lonza: cell therapy contract manufacturing, 201910– supply UCART cell therapy candidates by Lonza in Geleen (NL) |
2019-10-01 |
| Oncimmune–IPF Partners: credit, 201909– 202309 credit facility €8.5m four year incl warrant for 2m new ordinary shares IPF Management SA |
2019-09-20 |
| Menarini–BlueBee: bioinformatics, –201909 collab developm of MSBiosuite using BlueBee genomics data platoform |
2019-09-19 |
| Novigenix–BioLizard: bioinformatics, 201909– collab developm of AI-based bioinformatics algorithm to support developm of tests for LITOseek platform |
2019-09-19 |
| Versantis–SEVERAL: investment, 201909 financing round Series B CHF16m led by Swisscanto Invest by ZKB |
2019-09-18 |
| Pharvaris–Bain Capital: investment, 201909 financing round Series B totalling $66m incl new + co-investor Bain Capital Life Sciences |
2019-09-10 |
| Pharvaris–Foresite Capital: investment, 201909 financing round Series B totalling $66m incl new + lead investor Foresite Capital |
2019-09-10 |
| Pharvaris–Idinvest Partners: investment, 201909 financing round Series B totalling $66m incl existing + co-investor Idinvest Partners |
2019-09-10 |
| Pharvaris–Kurma: investment, 201909 financing round Series B totalling $66m incl existing + co-investor Kurma Partners |
2019-09-10 |
| Pharvaris–Life Sciences Partners: investment, 201909 financing round Series B totalling $66m incl existing + co-investor LSP |
2019-09-10 |
| Pharvaris–Rockefeller: investment, 201909 financing round Series B totalling $66m incl new + co-investor Venrock Partners |
2019-09-10 |
| Pharvaris–SEVERAL: investment, 201909 financing round Series B $66m led by Foresite Capital |
2019-09-10 |
| Pharvaris–VenBio: investment, 201909 financing round Series B totalling $66m incl new + co-investor venBio Partners |
2019-09-10 |
| iStar Medical–Belgium (govt): investment, 201909 financing round Series C totalling €40m incl existing + co-investor SFPI-FPIM |
2019-09-05 |
| iStar Medical–BNP Paribas: investment, 201909 financing round Series C totalling €40m incl new + co-investor BNP Paribas Fortis Private Equity |
2019-09-05 |
| iStar Medical–Capricorn Venture Partners: investment, 201909 financing round Series C totalling €40m incl existing + co-investor Capricorn |
2019-09-05 |
| iStar Medical–Earlybird: investment, 201909 financing round Series C totalling €40m incl new + co-investor Earlybird |
2019-09-05 |
| iStar Medical–Gimv: investment, 201909 financing round Series C totalling €40m incl new + co-lead investor Gimv |
2019-09-05 |
| iStar Medical–Life Sciences Partners: investment, 201909 financing round Series C totalling €40m incl new + co-lead investor LSP Health Economics 2 |
2019-09-05 |
| iStar Medical–Optimum Strategic Communications: public relations, 201909 service existent by Optimum |
2019-09-05 |
| iStar Medical–SEVERAL: investment, 201905 financing round Series C €40m led by LSP + Gimv |
2019-09-05 |
| iStar Medical–Wallonia (govt): investment, 201909 financing round Series C totalling €40m incl existing + co-investor SRIW |
2019-09-05 |
| Curetis–OpGen: investment, 201909– reverse merger with Curetis shareholders holding 72.5% of combined entity |
2019-09-04 |
| Uniqure–SEVERAL: investment, 201909 public offering $225m+$34m with 4.9m+734k ordinary shares at $46/share |
2019-09-04 |
| Achilles Therapeutics–RA Capital Management: investment, 201909 financing round Series B totalling £100m incl new + lead investor RA Capital |
2019-09-03 |
| Achilles Therapeutics–SEVERAL: investment, 201909 financing round Series B £100m led by RA Capital Management |
2019-09-03 |
| Curetis–HC Wainwright: investment banking, 201908– supply service Curetis retains HC Wainwright to evaluate all strategic options |
2019-08-12 |
| Blue Heron–Eurofins: investment, 201908 acquisition of Blue Heron Biotech by Eurofins Genomics LLC |
2019-08-06 |
| Imcyse–Andrew Lloyd Associates: public relations, 201908 service existent by ALA |
2019-08-05 |
| Alizé Pharma–SEVERAL: investment, 201907 financing round Series A €67m of Alizé Pharma 3 led by LSP |
2019-07-31 |
| Ako med–Curetis: Unyvero system, 201907– distribution excl 3y Unyvero A50 system + cartridges in Serbia + Bosnia + North Macedonia + Montenegro |
2019-07-30 |
| Breath Therapeutics–Zambon: investment, 201907 acquisition €140m + €360m milestones by Zambon |
2019-07-25 |
| Medicxi Ventures–JnJ: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–Novartis: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| AM-Pharma–SEVERAL: investment, 201907 financing round €116m co-led by LSP + Andera Partners |
2019-07-16 |
| Ncardia–Evotec: investment, 201907 acquisition €na of iPSC assets + 17 strong team of bankrupt Ncardia AG in Cologne |
2019-07-15 |
| Galapagos–Gilead: investment, 201907 equity investment $1.1b at €140.59/share raising share from 12.3% to 22% as part of collab |
2019-07-14 |
| Gilead–Galapagos: drug research + development, 201907–202906 strategic 10y collab $3.9b upfront + $1.1b equity investment + milestones |
2019-07-14 |
| Citryll–BrightGene: investment, 201907 first closing of a targeted €15m financing round Series A incl investor BrightGene International Ltd |
2019-07-03 |
| Citryll–Curie Capital: investment, 201907 first closing of a targeted €15m financing round Series A incl investor Curie Capital |
2019-07-03 |
| Citryll–ModiQuest: investment, 201907 first closing of a targeted €15m financing round Series A incl investor ModiQuest BV |
2019-07-03 |
| Citryll–Netherlands (govt): investment, 201907 first closing of a targeted €15m financing round Series A incl investor BOM Brabant Ventures |
2019-07-03 |
| Citryll–SEVERAL: investment, 201907 first closing of targeted €15m financing round Series A with ModiQuest + BOM + BrightGene + Curie Capital |
2019-07-03 |
| CryoTherapeutics–SEVERAL: investment, 201906 financing round Series B €7m incl equity + debt + non-dilutive cash advances |
2019-06-27 |
| Sanifit–Forbion: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Forbion Capital Partners |
2019-06-26 |
| Sanifit–Gilde Investment: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Gilde Healthcare |
2019-06-26 |
| Sanifit–la Caixa: investment, 201906 financing round Series D totalling €55.2m incl existing + lead investor Caixa Capital Risc |
2019-06-26 |
| Sanifit–SEVERAL: investment, 201906 financing round Series D €55.2m led by Caixa Capital Risc |
2019-06-26 |
| Sanifit–SEVERAL: investment, 201906c capitalisation of €17m of convertible bonds |
2019-06-26 |
| Forendo Pharma–Vesalius Biocapital: investment, 201906 existent investment of Vesalius Biocapital III fund |
2019-06-25 |
| Sword Health–Vesalius Biocapital: investment, 201906 existent investment of Vesalius Biocapital III fund |
2019-06-25 |
| Transplant Genomics–Eurofins: investment, 201906 acquisition of Transplant Genomics Inc by Eurofins |
2019-06-25 |
| Vesalius Biocapital–SEVERAL: investment, 201906 final closing of €120m Vesalius Biocapital III fund |
2019-06-25 |
| Gamida Cell–Lonza: cell therapy contract manufacturing, 201906– supply multi-year future commercial production of omidubicel by Lonza in Geleen (NL) |
2019-06-19 |
| Imcyse–SEVERAL: investment, 201906 financing round Series B €28m led by LSP |
2019-06-18 |
| Kiadis–SEVERAL: investment, 201905 private placment €27.6m with 3.68m new shares at €7.5/share |
2019-05-30 |
| Kiadis–Be The Match: cell therapy, 201905– collab logistical + technological solutions for ATIR101 developm in US + CA by Be The Match |
2019-05-22 |
| Storm Therapeutics–Merck (DE): investment, 201905 financing round Series A extension totalling £14m incl existing investor M Ventures |
2019-05-20 |
| Storm Therapeutics–SEVERAL: investment, 201905 financing round Series A extension £14m bringing total round to £30m incl new investor Seroba LS |
2019-05-20 |
| DNA Script–Life Sciences Partners: investment, 201905 financing round Series B totalling $38.5m incl new + lead investor LSP |
2019-05-16 |
| Inovio–Qiagen: molecular companion diagnostics, 201905– collab developm of CDx for VGX-3100 DNA-based immunotherapy for cervical dysplasia |
2019-05-16 |
| Icometrix–Bertarelli Group: investment, 201905 financing round totalling $18m incl new + lead investor Forestay Capital |
2019-05-14 |
| Icometrix–Capricorn Venture Partners: investment, 201905 financing round totalling $18m incl existing + co-investor Capricorn Venture Partners |
2019-05-14 |
| Icometrix–Optum Ventures: investment, 201905 financing round totalling $18m incl new + co-investor Optum Ventures |
2019-05-14 |
| Icometrix–SEVERAL: investment, 201905 financing round $18m led by Forestay Capital + incl Optum Ventures + Capricorn Venture Partners |
2019-05-14 |
| Confo Therapeutics–BioGeneration Ventures: investment, 201905 financing round Series A totalling €30m incl new + lead investor BGV |
2019-05-07 |
| Confo Therapeutics–Capricorn Venture Partners: investment, 201905 financing round Series A totalling €30m incl existing + co-investor Capricorn HTF |
2019-05-07 |
| Confo Therapeutics–Flanders (govt): investment, 201905 financing round Series A totalling €30m incl existing + co-investor PMV |
2019-05-07 |
| Confo Therapeutics–Fund+: investment, 201905 financing round Series A totalling €30m incl new + co-investor Fund+ |
2019-05-07 |
| Confo Therapeutics–Perceptive Advisors: investment, 201905 financing round Series A totalling €30m incl new + co-investor Perceptive Advisors |
2019-05-07 |
| Confo Therapeutics–Qbic: investment, 201905 financing round Series A totalling €30m incl existing + co-investor Qbic |
2019-05-07 |
| Confo Therapeutics–SEVERAL: investment, 201905 financing round Series A €30m led by BGV + co-led by Wellington Partners |
2019-05-07 |
| Confo Therapeutics–Univ Michigan: investment, 201905 financing round Series A totalling €30m incl existing + co-investor MINTS |
2019-05-07 |
| Confo Therapeutics–V-Bio Ventures: investment, 201905 financing round Series A totalling €30m incl existing + co-investor V-Bio Ventures |
2019-05-07 |
| Confo Therapeutics–VIB: investment, 201905 financing round Series A totalling €30m incl existing + co-investor VIB |
2019-05-07 |
| Confo Therapeutics–Wellington Partners: investment, 201905 financing round Series A totalling €30m incl new + co-lead investor Wellington Partners |
2019-05-07 |
| Promethera–Ci:z Investment: investment, 201905 financing round Series D totalling €39.7m incl new + co-investor Ci:z Investment LLP (JP) |
2019-05-07 |
| Promethera–Korea Investment Partners: investment, 201905 financing round Series D totalling €39.7m incl new + co-investor Korea Investment Partners |
2019-05-07 |
| Promethera–Medipal: investment, 201905 financing round Series D totalling €39.7m incl new + co-investor Medipal Holdings Corp |
2019-05-07 |
| Promethera–Mirae Asset: investment, 201905 financing round Series D totalling €39.7m incl new + co-investor Mirae Asset Capital |
2019-05-07 |
| Promethera–Mitsui: investment, 201905 financing round Series D totalling €39.7m incl existing + co-investor Mitsui & Co Global Investment Inc |
2019-05-07 |
| Promethera–SEVERAL: investment, 201905 financing round Series D totalling €39.7m incl Belgian private investors as co-investors |
2019-05-07 |
| Promethera–SEVERAL: investment, 201905 financing round Series D €39.7m co-led by Itochu Corp + Shinsei Capital Partners |
2019-05-07 |
| Promethera–Shinsei Capital: investment, 201905 financing round Series D totalling €39.7m incl new + co-lead investor Shinsei Capital Partners |
2019-05-07 |
| Promethera–Six Snow: investment, 201905 financing round Series D totalling €39.7m incl new + co-investor family office Six Snow |
2019-05-07 |
| Enzyre–EU (govt): grant, 201904 EFRO grant €2m |
2019-04-30 |
| Enzyre–Optimum Strategic Communications: public relations, 201904 service existent by Optimum |
2019-04-30 |
| Enzyre–SEVERAL: investment, 201904 closing of seed financing round |
2019-04-30 |
| SGS–Veeva Systems: clinical research software, 201904– supply global implementation of Veeva Vault CTMS by SGS |
2019-04-30 |
| JnJ–Iktos: drug discovery services, 201904– collab using AI technology for small molecule drug discovery projects Janssen |
2019-04-29 |
| LabCorp–Biocartis: molecular diagnostics, 201904– collab ww €na offering of Idylla platform + oncology assays by Covance for drug development |
2019-04-23 |
| CytoSen Therapeutics–Kiadis: investment, 201904– acquisition merger in shares with 1.94m shares (7.4%) upfront plus 5.82 shares milestones |
2019-04-17 |
| Bruker Corp–Univ Nijmegen: mass spectrometry, 201904– collab establishment of joint Center of Excellence for Translational Omics at RUMC TML |
2019-04-16 |
![[LSBNL] Life-Sciences-Benelux.com - The Benelux Life Sciences Web Portal](/images/basics/lsbnl-life-sciences-benelux-portal-logo-2019.png){kind=logo}
Date![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
![Picture [iito] LSUS iitoLifeScience Transatlantic Life Sciences 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
